Characteristics | Responders (N = 38) | Non-responders (N = 16) | ρ-value |
---|---|---|---|
Age, median (years, min-max) | 47,5 [18–79] | 44 [28–80] | 1 |
Sex (men/women) | 20/18 (53/47) | 6/10 (37.5/62.5) | 0.4 |
Ethnicity | |||
Caucasian Maghrebis West-Indies | 26 (69) 7 (18) 5 (13) | 12 (75) 1 (6) 3 (19) | 0.7 0.4 0.7 |
Median disease duration (months, IQR) | 45 [13.5–98] | 38,5 [17–100] | 0.8 |
Main involved organ | |||
Central nervous system Lungs Systemic disease Liver Eye Peripheral nervous system Muscles Joints Others | 13 (34) 4 (10.5) 4 (10.5) 4 (10.5) 3 (8) 3 (8) 2 (5) 1 (3) 4 (10.5) | 0 3 (19) 6 (37.5) 0 2 (12.5) 0 1 (6) 3 (19) 1 (6) | 0.006 0.4 0.06 0.6 0.3 0.07 1 0.5 0.8 |
Lymphopenia CD4+ count (×109/L) | 25 (69) 0.54 | 10 (67) 0.72 | 1 0.3 |
Increased gamma globulin levels | 5 (18.5) | 4 (36) | 0.4 |
Inflammation with elevated CRP | 19 (54) | 6 (37.5) | 0.4 |
Elevated angiotensin-converting enzyme | 13 (37) | 5 (36) | 1 |
Median number of previous therapies (IQR) | 2 [1–2.75] | 2 [1–2.25] | 0.7 |
Number of patients who required an increased doses of oral steroids | 20 (53) | 5 (31) | 0.2 |
Median dose of oral steroids (mg/day, IQR) | 17.5 [2.5–40] | 20 [12–51] | 0.3 |
Pulses of methylprednisolone | 13 (34) | 2 (12.5) | 0.2 |
Concomitant immunosuppressant | 8 (21) | 3 (19) | 1 |